The last few days have seen a flurry of biotech IPO news, continuing the strong start to 2026, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings. Californian start-up Alamar ...

Californian protein sequencing company Alamar Biosciences is seeking an IPO worth up to $159 million amid a growing boom in life sciences public offerings. The medtech is looking to shift around 9.4 ...

April 13 (Reuters) - Alamar Biosciences and Kailera Therapeutics kicked off roadshows for their U.S. initial public offerings on Monday, aiming for billion-dollar-plus valuations ‌as biotech companies ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company hired close to 100 ...

Alamar Foods Co.’s shareholders authorized the board of directors to pay interim dividends for 2026, on a semiannual or quarterly basis. In a statement to Tadawul, the company said the decision came ...

Alamar Biosciences, Inc. (ALMR) has filed to raise capital via an IPO that may exceed $100 million, according to an S-1 registration statement. The company has developed a protein biomarker analysis ...

A24 has released the trailer for “Backrooms,” an upcoming sci-fi horror film starring Renate Reinsve and Chiwetel Ejiofor. Directed by Kane Parsons in his feature directorial debut, “The Backrooms” is ...

Warner Bros. and DC have unveiled a new trailer for Supergirl, previewing the titular superhero’s (Milly Alcock) battles with Krem of the Yellow Hills (Matthias Schoenaerts) and more. The trailer ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The death of founder Yuling Luo ...

The fourth-quarter net profit declined 19% to SAR 17.5 million from SAR 21.6 million in Q4 2024. Compared to Q3 2025, net earnings rose 11.7% from SAR 15.7 million. Shareholders’ equity, after ...

Weight loss drug developer Kailera Therapeutics (KLRA) and Alamar Biosciences (ALMR), a commercial-stage proteomics company, filed for their respective U.S. initial public offerings with the SEC on ...

The series, a new adaptation of J.K. Rowling's novels, premieres Christmas 2026. By Lexi Carson Associate Editor The first season of the multiseason series is set to follow Rowling’s first novel, ...